AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19318667
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL of normal saline solution; n = 325)
Trial: 15014015
Drug: Temozolomide (TEM)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TEM) administered orally daily on days 1-5 and BCNU administered intravenously either on day 1 before TEM (Seq B‐‐>T) or day 5 after TEM (Seq T‐‐>B).
Trial: 2755859
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine (MS Contin, Purdue Frederick Co.)
Trial: 1752851
Drug: Oral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral route of administration
Trial: 28492195
Drug: Inhalation route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation route of administration
Trial: 23273434
Drug: Bortezomib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.5 mg/m² biweekly on days 1, 4, 8, and 11 of a 21-day cycle (arm A)
Trial: 16855170
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (14 patients on other anti-TNF therapies and 20 negative controls)
Trial: 9029744
Drug: 12.5-cm2 once-a-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5-cm2 once-a-week adhesive patch
Trial: 3263890
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of prednisone given daily for 5 days
Trial: 28502831
Drug: Sucralose (333.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (333.3 mg, encapsulated, 3x/day at mealtimes)
Trial: 16139331
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR 2.8‐4.2)
Trial: 10776741
Drug: Aspirin 160
RxNorm normalized name: aspirin 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 160 mg daily
Trial: 8438096
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol controlled release (SCR) 8 mg b.d.
Trial: 26242401
Drug: Interactive VRET
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive VRET plus conventional analgesics
Trial: 26242401
Drug: Conventional analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional analgesics alone
Trial: 12743142
Drug: Whole-pelvic radiotherapy
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-pelvic radiotherapy (WP RT) + Adjuvant hormonal therapy (AHT)
Trial: 12743142
Drug: Prostate-only radiotherapy
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate-only radiotherapy (PO RT) + Adjuvant hormonal therapy (AHT)
Trial: 12743142
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal therapy (AHT)
Trial: 29788433
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt (400 g daily for 2 weeks)
Trial: 10628889
Drug: Imipramine (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50-100 mg/day)
Trial: 8688982
Drug: Moscontin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moscontin (30 mg)
Trial: 2091623
Drug: Monosodium glutamate
RxNorm normalized name: Monosodium Glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium glutamate (400 to 1600 mg)
Trial: 7350799
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline (0.5 mg)
Trial: 15830222
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 20 mg
Trial: 21514093
Drug: Hydrocortisone at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone at 1.5 μg/kg per minute (STRESS)
Trial: 21514093
Drug: Hydrocortisone at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone at 3.0 μg/kg per minute (PHARM)
Trial: 11356728
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: 3595575
Drug: Gastrozepin 10
RxNorm normalized name: Gastrotsepin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrozepin 10 mg
Trial: 19630495
Drug: Narcotics and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotics and acetaminophen alone
Trial: 18555931
Drug: Novopharm tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novopharm tablet
Trial: 10442525
Drug: Epinastine 20
RxNorm normalized name: epinastine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinastine 20 mg
Trial: 8621275
Drug: RRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRP plus neoadjuvant hormonal therapy
Trial: 8621275
Drug: RRP without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RRP without hormonal therapy
Trial: 19592234
Drug: Adjuvant therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapies
Trial: 30548555
Drug: ProDesign R
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProDesign R [PDR; size 25, .06 taper; Easy, Belo Horizonte, Brazil]
Trial: 30548555
Drug: Mtwo [MO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mtwo [MO; size 25, .06 taper; VDW, Munich, Germany]
Trial: 30548555
Drug: Reciproc [REC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reciproc [REC; size 25, .08 taper; VDW, Munich, Germany]
Trial: 30278067
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (10 mg/kg)
Trial: 30278067
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (3 g)
Trial: 30278067
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo (60 ml physiological saline)
Trial: 2193199
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no insulin treatment)
Trial: 17358096
Drug: Rectally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectally administered oxcarbazepine suspension (300 mg and 450 mg doses)
Trial: 7988364
Drug: Hydrochlorothiazide (HCT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT; <= 25 mg daily)
Trial: 3141491
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day parenteral folinic acid
Trial: 3141491
Drug: 50 mg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/week parenteral folinic acid
Trial: 19364291
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg of MPH
Trial: 10628766
Drug: Prednisone withdrawal
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone withdrawal (tapered over 8 weeks to 0 mg/day)
Trial: 10628766
Drug: Prednisone maintenance
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone maintenance (10 mg/day)
Trial: 7707112
Drug: High-dose experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose experimental therapy
Trial: 7707112
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment or experimental agent
Trial: 7707112
Drug: Different therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different therapies for a 6-month addition to life expectancy
Trial: 7707112
Drug: Randomization to
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization to a clinical trial comparing high-dose with standard chemotherapy
Trial: 2390879
Drug: Inosine, 50‐90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine, 50‐90 mg/kg daily in divided doses
Trial: 24004292
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (200,000 IU for 2 months, then 100,000 IU monthly for 18 months)
Trial: 12138146
Drug: gentamicin/citrate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gentamicin/citrate (40 mg/ml and 3.13% citrate; ratio 2:1)
Trial: 12138146
Drug: heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin (5000 U/ml)
Trial: 9570264
Drug: Hypotonic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic solution (160 mOsmol/kg)
Trial: 16758849
Drug: Isotonic solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic solution
Trial: 8214753
Drug: Edrophonium (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (0.1, 0.2, 0.4, or 1 mg/kg)
Trial: 8214753
Drug: Neostigmine (0.005,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg/kg)
Trial: 2568767
Drug: Edrophonium (0.44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (0.44 +/- 0.11 mg/kg with atracurium and 0.46 +/- 0.12 mg/kg with vecuronium)
Trial: 25558975
Drug: Motor control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor control therapy
Trial: 19779321
Drug: Lersivirine (UK-453,061)
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lersivirine (UK-453,061) 100 mg twice daily
Trial: 19779321
Drug: Lersivirine (UK-453,061)
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lersivirine (UK-453,061) 500 mg twice daily
Trial: 19779321
Drug: Lersivirine (UK-453,061)
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lersivirine (UK-453,061) 750 mg once daily
Trial: 15900307
Drug: Soy supplement
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplement (30 g soy protein, 9 g cotyledon fibre, 100 mg isoflavones)
Trial: 15900307
Drug: Soy supplement
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplement
Trial: 12802453
Drug: Immunomodulatory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory therapy with larifan, ridostin, and viferon for 1 month
Trial: 9796889
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg orally twice daily
Trial: 23477506
Drug: Synbiotic supplement
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement for 8 weeks
Trial: 15163340
Drug: T4/T3 combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T4/T3 combination therapy
Trial: 20466363
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg conjugated estrogens orally for 7 days
Trial: 20466363
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g conjugated estrogens vaginally for 7 days
Trial: 9123711
Drug: High-dose yohimbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose yohimbine hydrochloride (36 mg per day orally)
Trial: 1971641
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g)
Trial: 29413356
Drug: 4g/day of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g/day of prescription omega‐3 fatty acids (P‐OM3) for 16 weeks
Trial: 27095306
Drug: Sonidegib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib (200 mg or 800 mg doses)
Trial: 22281018
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of anastrozole (1 mg)
Trial: 22281018
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of anastrozole (1 mg)
Trial: 20498181
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg THC twice daily
Trial: 18365856
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone replacement therapy (1 mg estradiol + 0.125 mg trimegestone)
Trial: 18365856
Drug: Nasal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal hormone replacement therapy (150 or 300 microg estradiol + 200 mg micronized progesterone)
Trial: 9536660
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg) in three divided doses
Trial: 9536660
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (400 mg)
Trial: 10657288
Drug: Carbamazepine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (200 mg)
Trial: 3338255
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between strength and amount of walking (daily steps)
Trial: 28915900
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus vinorelbine (standard treatment)
Trial: 26403745
Drug: SMOF (lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMOF (lipid emulsion formulation containing soybean oil, medium chain triglycerides, olive oil, and fish oil)
Trial: 23497590
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral glucocorticoid dosing
Trial: 23497590
Drug: Reduced oral
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced oral glucocorticoid dosing
Trial: 18202589
Drug: Pueraria mirifica
RxNorm normalized name: PUERARIA MIRIFICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pueraria mirifica (20, 30, or 50 mg once daily for 24 weeks)
Trial: 18202589
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsules once daily for 24 weeks)
Trial: 16279282
Drug: Hormone treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone treatment (unopposed conjugated estrogens (CEE) 0.625 mg/day if without a uterus; CEE combined with medroxyprogesterone acetate (MPA) 2.5 mg/day otherwise)
Trial: 7942668
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with omeprazole 40 mg, amoxicillin, and metronidazole
Trial: 27255923
Drug: Existing program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing program with monthly growth monitoring and nutritional/hygiene education (T0)
Trial: 17805230
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (26+/‐5 g protein containing 44+/‐8 mg isoflavones per day)
Trial: 17805230
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein isolate (26+/‐5 g protein per day)
Trial: 20132103
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg
Trial: 14739037
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cisplatin 80 mg/m2 on day 1; vindesine 3 mg/m2 on days 1 and 8: x3 courses)
Trial: 25936321
Drug: Atorvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin monotherapy
Trial: 25577723
Drug: Atorvastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin plus ezetimibe (10 mg) daily
Trial: 24079283
Drug: Colesevelam (3750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3750 mg/d) with niacin titration
Trial: 24079283
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with niacin titration
Trial: 21133824
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg allopurinol daily for 12 weeks
Trial: 3057844
Drug: Propafenone 675
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 675 mg/day
Trial: 7135
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg
Trial: 6093960
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg
Trial: 25332478
Drug: Lactobacillus paracasei
RxNorm normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus paracasei DG (24 billion viable cells daily for 4 weeks)
Trial: 22054033
Drug: Super Poligrip®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super Poligrip® Free (cream)
Trial: 22054033
Drug: Cream adhesives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream adhesives
Trial: 11837527
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy interventions
Trial: 9651905
Drug: HRT-group: Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT-group: Sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate + vitamin D3 300 IU/day + calcium lactate 500 mg/day (n = 31)
Trial: 9651905
Drug: non-HRT-group: Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-HRT-group: Calcium lactate 500 mg/day + vitamin D3 300 IU/day (n = 33)
Trial: 7898842
Drug: Intravaginal 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal 2.5 mg of PGE2 gel every hour
Trial: 7898842
Drug: Intravaginal 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal 2.5 mg of PGE2 gel every 6 hours
Trial: 2655717
Drug: Timiperone 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timiperone 1 mg, 3 mg, 6 mg
Trial: 2655717
Drug: Sulpiride 100
RxNorm normalized name: sulpiride 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 100 mg, 300 mg, 600 mg
Trial: 792642
Drug: Fenoterol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (1 mg)
Trial: 9510443
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (recombinant GH 0.1 IU/kg/day)
Trial: 3124593
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat intake (450 mg.kg‐1.d‐1) at 60 kcal.kg‐1.d‐1
Trial: 3124593
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat intake (450 mg.kg‐1.d‐1) at 60 kcal.kg‐1.d‐1
Trial: 24755123
Drug: Linagliptin 2.5
RxNorm normalized name: linagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 2.5 mg with 500 mg, 850 mg, or 1,000 mg metformin (FDC)
Trial: 24755123
Drug: Individual tablets
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual tablets of linagliptin and metformin (FP)
Trial: 17619862
Drug: Information emphasizing
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information emphasizing patch benefits (n = 25)
Trial: 17619862
Drug: Nicotine-dose instructions
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine-dose instructions (n = 25)
Trial: 12668365
Drug: Paroxetine 40
RxNorm normalized name: PARoxetine 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 40 mg/day
Trial: 14628989
Drug: Paroxetine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 60 mg/day
Trial: 10023508
Drug: L-tryptophan 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan 6 g per day
Trial: 373085
Drug: phenylbutazone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenylbutazone (100 mg 3 times daily)
Trial: 7113925
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily safety lecture group (S)
Trial: 28278010
Drug: Valerian 530
RxNorm normalized name: valerian 530 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian 530 mg capsule twice per day for two months
Trial: 28278010
Drug: Placebo 530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 530 mg capsule (starch)
Trial: 26915963
Drug: Need supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Need supportive (NS) SMS sent twice weekly for 10 weeks
Trial: 24914136
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (transfusions/chelation)
Trial: 21761190
Drug: LipoNasal n
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipoNasal n nasal spray (LNM)
Trial: 21761190
Drug: LipoNasal n
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipoNasal n nasal spray and Tears Again eye spray combination therapy (LTC)